Expression of survivin and its splicing variants and VEGF in human breast cancer tissue and their clinical significance

doi:10.3877/cma.j.issn.1674-0793.2009.04.004

Abstract

Abstract:

Objective

To investigate the expression of survivin and its splicing variants survivin-△Ex3,survivin-2B and VEGF mRNA in human breast cancer and its relation to clinicopathological and parameters.

Methods

The expression of survivin and its splicing variants survivin-△Ex3, survivin-2B and VEGF mRNA was determined by both reverse transcription-polymerase chain reaction (RT-PCR)and semi-quantitative electrophoresis in 100 breast cancer and adjacent normal breast tissue.The protein expression of estrogen receptor(ER),progesterone receptor (PR),Her-2 gene was detected by immuno-histochemical method.

Results

The expressions of survivin and its splicing variants survivin-△Ex3, survivin-2B mRNA in the breast cancer tissues were significantly higher than the adjacent normal breast tissues(P<0.05).The expressions of VEGF mRNA in the breast cancer tissues was significantly higher than the adjacent normal breast tissues (P<0.05).The expression of survivin-△Ex3, survivin-2B mRNA positively correlated with lymph node metastasis (P<0.05).

Conclusions

The expression of survivin and its splicing variants survivin-△Ex3, survivin-2B and VEGF are correlated with breastcancercarcinogenesisanddevelopment.Itmaybeusedtogetherwithotherprognosticmarkers(ER,PR,HER-2)in the prognosis and of breastcancer.

Key words: Breastcarcinoma, Survivin, Splicevariants, VEGF

Le-hong ZHANG, Ji-peng YANG, Yan-hua PENG, Yong HE. Expression of survivin and its splicing variants and VEGF in human breast cancer tissue and their clinical significance[J]. Chinese Archives of General Surgery(Electronic Edition), 2009, 03(04): 274-279.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2009.04.004

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2009/V03/I04/274

Figures/Tables 7

References 15

1	Hodgson SV, Morrison PJ, Irving M. Breast cancer genetics:Unsolved questions and open perspectives in an expanding clinical practice. Am J Med Genet C Semin Med Genet,2004,129C(1):56-64.
2	Devereaux QL,Takahashi R,Salvesen GS,et al.X-linked IAP is a direct inhibitor of cell-death proteases.Nature,1997,388(6639):300-304.
3	Adida C,Croty PL,McGrath J,et al.Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation.Am J Pathol,1998,152(1):43-49.
4	Ikeguchi M,Ueda T,Sakatani T,et al.Expression of survivin messenger RNA correlates with poor prognosis in patients with hepatocellular carcinoma.Diagn Mol Pathol,2002,11(1):33-40.
5	Junhe Li, Wenjing He, Youjian He. The prediction of recurrence and survival of patients with Dukes’B colorectal cancer after curative resection with immunohistochemical detection of survivin and Livin expressions.Chinese-German Journal of Clinical Oncology,2008,7(1):22-26.
6	Notarbartolo M,Cervello M,Giannitrapani L,et al.Expression of IAPs and alternative splice variants in hepatocellular carcinoma tissues and cells.Ann N Y Acad Sci,2004,1028:289-293.
7	Takashima H,Nakajima T,Moriguchi M,et al.In vivo expression patterns of survivin and its splicing variants in chronic liver disease and hepatocellular carcinoma.Liver Int,2005,25(1):77-84.
8	贺勇,章乐虹,张昊,等.Survivin 及其剪接变异体survivin-△Ex3,survivin-2B mRNA 在乳腺癌中的表达和临床意义.热带医学杂志,2007,7(12):1149-1104.
9	Ryan B,O'Donovan N,Browne B,et al.Expression of survivin and its splice variants survivin-2B and survivin-DeltaEx3 in breast cancer.Br J Cancer,2005,92(1):120-124.
10	Xiong H,Yu S,Zhuang L,et al.Changes of survivin mRNA and protein expression during paclitaxel treatment in breast cancer cells. J Huazhong Univ Sci Technolog Med Sci,2007,27(1):65-67.
11	Ferrara N,Gerber HP,Lecouter J.The biology of VEGF and its receptors.Nat Med,2003,9(6):669-676.
12	Kennedy SM,O’Drscoll L,Purcell R.Prognostic importance of survivin in breast cancer.Br J Cancer,2003,88(7):1077-1083.
13	Howard EM, Lau SK, Lyles RH, et al. Correlation and expression of p53, HER-2, vascular endothelial growth factor (VEGF), and e-cadherin in a high-risk breast-cancer population.Int J Clin Oncol,2004,9(3):154-160.
14	O’Connor DS, Schechner JS, Adida C, et al. Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am J Pathol, 2000,156(2):393-398.
15	Fokman J. Seminons in medicine of the Beth Israel Hospital, Boston. Clinical application of research on angiogenesis. N Engl Med, 1995, 333:1757-1763.

引物名称	上游引物	下游引物	扩增片段
Survivin	5-GAGAACGAGCCAGACTTGGC-3	5-CCTCTGGTGCCACTTTCAAGA-3	461 bp
survivin-△Ex3	5-GCATGGGTGCCCCGACGTTG-3	5-GCTCCGGCCAGAGGCCTCAA-3	344 bp
survivin-2B	5-ACAACCAAACCTCACACTACTG-3	5-ATAGATCCCATTACAGACAGCG-3	530 bp
VEGF	5-GGAGCTTCAGGACATTGCTGTG-3	5-GGAGGAAGGTCAACCACTCAC-3	353 bp
GAPDH	5-AGTCCACTGGCGTCTTCAC-3	5-GCTTGACAAAGTGGTCGTTGAG-3	639 bp

引物名称	上游引物	下游引物	扩增片段
Survivin	5-GAGAACGAGCCAGACTTGGC-3	5-CCTCTGGTGCCACTTTCAAGA-3	461 bp
survivin-△Ex3	5-GCATGGGTGCCCCGACGTTG-3	5-GCTCCGGCCAGAGGCCTCAA-3	344 bp
survivin-2B	5-ACAACCAAACCTCACACTACTG-3	5-ATAGATCCCATTACAGACAGCG-3	530 bp
VEGF	5-GGAGCTTCAGGACATTGCTGTG-3	5-GGAGGAAGGTCAACCACTCAC-3	353 bp
GAPDH	5-AGTCCACTGGCGTCTTCAC-3	5-GCTTGACAAAGTGGTCGTTGAG-3	639 bp

分组	例数	survivin	survivin-△Ex3	survivin-2B	VEGF mRNA
癌组织	100	91	72	75	79
癌旁组织	100	13	6	9	5
χ²值		137.794	91.551	89.409	112.397
P值		0.000	0.000	0.000	0.000

分组	例数	survivin	survivin-△Ex3	survivin-2B	VEGF mRNA
癌组织	100	91	72	75	79
癌旁组织	100	13	6	9	5
χ²值		137.794	91.551	89.409	112.397
P值		0.000	0.000	0.000	0.000

指标	例数	survivin			survivin-△Ex3			survivin-2B			VEGF
指标	例数	阳性数	χ²值	P值	阳性数	χ²值	P值	阳性数	χ²值	P值	阳性数	χ²值	P值
年龄
≤50	41	37	0.049	0.826	30	0.047	0.828	31	0.014	0.907	31	0.481	0.488
＞50	59	54			42			44			48
ER
+	66	60	0.002	0.965	45	1.404	0.236	48	0.535	0.465	54	0.929	0.335
-	34	31			27			27			25
PR
+	60	55	0.081	0.775	41	1.000	0.317	45	0.000	1.000	50	1.698	0.193
-	40	36			31			30			29
HER-2
+	38	34	0.174	0.676	30	1.467	0.226	29	0.057	0.812	29	0.266	0.606
-	62	57			42			46			50
肿块大小(cm)
≤2	48	45	0.852	0.356	33	0.484	0.487	35	0.214	0.644	36	0.890	0.345
＞2	52	46			39			40			43
淋巴结转移
+	42	36	2.470	0.116	23	10.674	0.001	25	9.250	0.002	35	0.820	0.365
-	58	55			49			50			44
临床病理分期
I～II	78	72	0.740	0.390	56	0.007	0.931	61	1.943	0.163	64	1.990	0.158
III～Ⅳ	22	19			16			14			15

Please choose a citation manager

Content to export